Merck KGaA points new tool at drug development
Merck is the oldest chemical and pharmaceutical company in the world with a founding that dates back to 1668. But don’t let its age fool you: Merck is also one of the biggest companies in the sector, and the healthcare giant is just as innovative and forward-looking as its younger rivals. It demonstrated this point ably last week, by being the first player in the space to adopt a new tool for drug development.
Merck is up 9% so far this year
SOURCE: Yahoo Finance
The tool in question is called the Shahky – a protein detection instrument that can penetrate the ‘noise’ one usually finds in similar data-analysis services. It generates a clear signal through selective targeting technology that it applies to “disease specific exosomes” while removing non-relevant background data.
If that last sentence hurts your brain, as an investor, this is all you really need to know: the instrument’s performance has been validated in a leading Boston hospital, and it could be a game-changer when it comes to drug development.
Merck has gotten access to the Shahky through an agreement with Exosome Diagnostics, and it is the first company to utilize the tool. Mario Morken, head of business development at Exosome Diagnostics, said:
“We are excited to bring first of its kind technologies, such as Shahky, to our partners. The Shahky instrument represents a disruptive technology for drug development and ultimately the clinic.”
According to a statement put out by both companies, the agreement will give Merck the ability to “help further the company’s drug development efforts in oncology and other therapeutic areas,” and includes “the full breadth of Exosome Diagnostics’ proprietary technology platforms,” – not just Shahky.
Dominion holds Merck KGaA in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.